Mar 26, 2019 7:00am EDT Can-Fite Announces Phase II Advanced Liver Cancer Top-Line Results for its Orphan/Fast Track Drug Namodenoson
Feb 27, 2019 7:00am EST Can-Fite to Participate in Bio Asia International Conference on March 5-6, 2019 in Tokyo
Feb 25, 2019 7:00am EST Can-Fite Expands its Namodenoson Distribution Deal with CKD in South Korea with NASH Indication
Feb 04, 2019 7:00am EST Can-Fite Receives Notice of Allowance From U.S. Patent and Trademark Office for Osteoarthritis Drug
Jan 30, 2019 7:00am EST Can-Fite’s Drugs’ Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal
Jan 03, 2019 8:02am EST Can-Fite to Participate in the Biotech Showcase™ 2019 and BIO One-on-One Partnering™@ JPM 2019 During the JP Morgan Healthcare Conference
Dec 10, 2018 7:00am EST Can-Fite Enters Into Collaboration Agreement to Explore Namodenoson’s Anti-NASH Effect With Icahn School of Medicine at Mount Sinai in NYC
